L-Selenocystine是selenocysteine的氧化二硒化物产物，具有强抗氧化活性。
Cas No.:29621-88-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
L-Selenocystine is an oxidation diselenide product of selenocysteine with strong antioxidant activity [1]. L-Selenocystine can promote the phosphorylation of JNK, p38 MAPK, ERK and Akt in cells, and induce the activation of caspase, PARP cleavage and DNA fragmentation [2]. L-Selenocystine has been widely used to induce apoptosis in various cancer cells and to generate reactive oxygen species (ROS)[3].
In vitro, L-Selenocystine treatment for 24 hours significantly inhibited the proliferation of HepG2 cells and L02 cells, with IC50 values of 71.880μM and 5.444μM, respectively[4]. Treatment with 50μM L-Selenocystine for 24 hours significantly inhibited the activation of Nrf2 and the nuclear translocation of downstream proteins in WiDr cells, and induced autophagy in the cells[5]. The combined treatment of 10μM L-Selenocystine and 5-fluorouracil (400μM) for 24 hours triggered mitochondrial-mediated apoptosis in A375 cells, inducing mitochondrial dysfunction and enhancing DNA damage[6].
In vivo, L-Selenocystine treatment via vein injection at a dose of 10mg/kg/day for 14 days effectively suppressed JEG-3 choriocarcinoma tumor xenograft growth in mice[7]. Every other day, 5mg/kg dose of L-Selenocystine and 2mg/kg dose of auranofin were injected via the tail vein for 16 days, which inhibited the tumor volume and weight of A549 human lung adenocarcinoma xenografts in nude mice, without affecting the body weight of the mice[8].
References:
[1] Chuai H, Zhang S Q, Bai H, et al. Small molecule selenium-containing compounds: Recent development and therapeutic applications[J]. European journal of medicinal chemistry, 2021, 223: 113621.
[2] Chen T, Wong Y S. Selenocystine induces S-phase arrest and apoptosis in human breast adenocarcinoma MCF-7 cells by modulating ERK and Akt phosphorylation[J]. Journal of agricultural and food chemistry, 2008, 56(22): 10574-10581.
[3] Chen T, Wong Y S. Selenocystine induces reactive oxygen species–mediated apoptosis in human cancer cells[J]. Biomedicine & Pharmacotherapy, 2009, 63(2): 105-113.
[4] Chen H, Su J, Chen D, et al. L-Selenocystine induce HepG2 cells apoptosis through ROS-mediated signaling pathways[J]. Biocell, 2022, 46(10): 2267.
[5] Hsu W L, Wang C M, Yao C L, et al. Blockage of Nrf2 and autophagy by L-selenocystine induces selective death in Nrf2-addicted colorectal cancer cells through p62-Keap-1-Nrf2 axis[J]. Cell Death & Disease, 2022, 13(12): 1060.
[6] Fan C, Chen J, Wang Y, et al. Selenocystine potentiates cancer cell apoptosis induced by 5-fluorouracil by triggering reactive oxygen species-mediated DNA damage and inactivation of the ERK pathway[J]. Free Radical Biology and Medicine, 2013, 65: 305-316.
[7] Zhao M, Hou Y, Fu X, et al. Selenocystine inhibits JEG-3 cell growth in vitro and in vivo by triggering oxidative damage-mediated S-phase arrest and apoptosis[J]. Journal of Cancer Research and Therapeutics, 2018, 14(7): 1540-1548.
[8] Fan C, Zheng W, Fu X, et al. Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo[J]. Cell death & disease, 2014, 5(4): e1191-e1191.
L-Selenocystine是selenocysteine的氧化二硒化物产物，具有强抗氧化活性[1]。L-Selenocystine能促进细胞内JNK、p38 MAPK、ERK和Akt的磷酸化，并诱导caspase激活、PARP裂解和DNA片段化[2]。L-Selenocystine已被广泛用于诱导多种癌细胞凋亡和产生活性氧（ROS）[3]。
在体外，L-Selenocystine处理24小时显著抑制了HepG2细胞和L02细胞的增殖，IC50值分别为71.880µM和5.444µM[4]。使用50µM的L-Selenocystine处理24小时，显著抑制了WiDr细胞中Nrf2的激活及下游蛋白的核转位，并诱导了细胞自噬[5]。联合使用10µM的L-Selenocystine和5-氟尿嘧啶（400 µM）处理24小时，引发了A375细胞中线粒体介导的凋亡，诱导线粒体功能障碍并增强了DNA损伤 [6]。
在体内，每日静脉注射10mg/kg剂量的L-Selenocystine，持续14天，有效抑制了小鼠体内JEG-3绒毛膜癌异种移植瘤的生长[7]。每隔一天通过尾静脉注射5mg/kg剂量的L-Selenocystine和2mg/kg剂量的金诺芬，持续16天，抑制了裸鼠中A549人肺腺癌异种移植瘤的体积和重量，且未影响小鼠的体重[8]。
| Cell experiment [1]: | |
Cell lines | HepG2 cells |
Preparation Method | HepG2 cells were cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS) and antibiotics (penicillin 100U/ml, streptomycin 0.1mg/ml) under normal conditions (5% CO2 with 95% humidified air). HepG2 cells (6×104 per well) were inoculated in 96-well cell culture plate and incubated at 37°C with 5% CO2 for 24h. Then, the cells were treated with 2μM, 4μM, 8μM, 16μM, and 32μM L-Selenocystine for 24h, respectively, and cell viability was measured. |
Reaction Conditions | 2, 4, 8, 16, and 32μM; 24h |
Applications | L-Selenocystine treatment reduced the cell viability of HepG2 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Female nude mice |
Preparation Method | Thirty female nude mice were divided into three groups. After adaptation for 1-week, JEG-3 cells (107 cells in 100µl serum-free medium) were subcutaneously injected into the left oxter of mice. After growing for 7 days (tumor volume was about 60mm3), the mice were administrated with L-Selenocystine. Group 1 was set as the control group without treatment and Group 2 was administrated with 10mg/kg of L-Selenocystine. L-Selenocystine was injected from the caudal vein every other day for 14 days (a total of eight times). After administration was completed, tumors were harvested and measured with the following formula: volume = L×w2/2, thereinto L was the maximal length and w was the width. |
Dosage form | 10mg/kg/day for 14 days; vein injection |
Applications | L-Selenocystine treatment significantly inhibited JEG-3 choriocarcinoma tumor xenograft growth in mice. |
References: | |
| Cas No. | 29621-88-3 | SDF | |
| 别名 | L-硒代胱氨酸 | ||
| Canonical SMILES | OC([C@@H](N)C[Se][Se]C[C@H](N)C(O)=O)=O | ||
| 分子式 | C6H12N2O4Se2 | 分子量 | 334.1 |
| 溶解度 | H2O : 5.88 mg/mL (17.60 mM; ultrasonic and warming and adjust pH to 1 with HCl and heat to 60°C) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9931 mL | 14.9656 mL | 29.9312 mL |
| 5 mM | 598.6 μL | 2.9931 mL | 5.9862 mL |
| 10 mM | 299.3 μL | 1.4966 mL | 2.9931 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet